S-Docs Unveils Next-Level Experience To Redefine Operational Efficiency
12.9.2023 19:35:00 EEST | Business Wire | Press release
S-Docs, a market leader in document automation and e-signature, today announced three major upgrades to its flagship document automation solution. Set to be released in separate installments, these updates include a consolidated document creation workflow, a best-in class template editor experience, and an AI-driven document assistant.
“S-Docs is innovating to redefine productivity for our customers,” said Brian Stimpfl, Chief Executive Officer at S-Docs. “This new product evolution will dramatically streamline our users' workflows to maximize operational efficiency and elevate the customer experience.”
The first update marks the largest customer experience overhaul in S-Docs history. Anticipated for release this month, this feature empowers users to generate, view, and distribute documents from their existing work interface. “What used to require multiple steps is now one fluid operation,” said Anand Narasimhan, Chief Technology Officer at S-Docs. “This transformation will mark a major shift in our customers’ approach to document automation and reinforces our dedication to seamless customer experiences.”
In addition, S-Docs is launching an entirely new template editor in early 2024. This redesigned, intuitive interface will streamline and democratize template creation across all levels and roles within an organization. “Our aim is to simplify the document lifecycle from start to finish,” stated Anand Narasimhan. “The new editor will allow any user to construct dynamic documents that are always connected to the people, processes, and data that go into them.”
Finally, S-Docs is introducing generative AI to its products in 2024. This innovation will enable customers with a document copilot, providing dynamic content generation and document analysis capabilities. “By integrating AI, we’re enabling both end users and administrators to achieve in seconds what used to take hours,” Anand Narasimhan explained. “With integrity at the heart of S-Docs’ core values, we’re developing our AI solutions within a zero-trust security framework to put data privacy first as we pave the way for a new era in document automation.”
“These updates represent a significant milestone in S-Docs’ vision to revolutionize the way organizations create, manage, and share information,” said Brian Stimpfl.
As businesses look to stay ahead in a rapidly changing landscape, S-Docs’ product enhancements are poised to set new benchmarks for operational efficiency.
To learn more about S-Docs, please visit www.sdocs.com.
About S-Docs:
S-Docs is a document automation and e-signature solution for Salesforce. Companies of all sizes in every industry rely on S-Docs to eliminate manual work and simplify complex processes, resulting in increased productivity, enhanced customer experiences, and accelerated business success.
The company is privately held with headquarters in New York and offices in Ann Arbor. Learn more at sdocs.com and follow us on LinkedIn.
Use of the term Salesforce are the trademarks of Salesforce.com, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230912664296/en/
Contact information
Dyana Quinlivan
dquinlivan@sdocs.com
(303)263-6741
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 202622.9.2026 16:30:00 EEST | Press release
Takeda(TSE:4502/NYSE:TAK)announced that new data from its oncology pipeline and portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress, taking place October 23-27, 2026, in Madrid, Spain. Key data will include a late-breaking abstract on arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343*) and two presentations on TAK-928 (Innovent R&D code: IBI363*). Clinical and real-world analyses of ALUNBRIG® (brigatinib) and FRUZAQLA® (fruquintinib) will also be shared at the congress. “Takeda’s data at ESMO reflect our commitment to delivering rapid progress for patients living with some of the most prevalent and challenging cancers, including advanced gastric cancer and immunotherapy-resistant and previously untreated non-small cell lung cancer,” said Phuong Khanh (P.K.) Morrow, M.D., Head of the Oncology Therapeutic Area Unit at Takeda. “Our mission is to advance new therapeutic approaches for patients who need more options or who remain underserved by cur
Quaise Energy Selected for Up to $25 Million in U.S. Department of Energy Support to Advance World's First Commercial Superhot Geothermal Power Plant22.9.2026 16:30:00 EEST | Press release
Quaise Energy, a leading developer of utility-scale superhot geothermal energy, today announced that it has been selected by the U.S. Department of Energy (DOE) for up to $25 million in funding under the Next-Generation Geothermal Field Tests and Geothermal Resource Characterization and Confirmation funding opportunity. The support brings the U.S. closer to commercializing superhot Enhanced Geothermal Systems — technology that could unlock firm, clean power from hot rock beneath virtually any geography in the country. The funding will advance Project Obsidian, the world's first commercial superhot geothermal power plant, in Central Oregon. It will support analysis of the drilling, stimulation, and flow results of the first two wells to optimize a third well at the Obsidian site. The three-well configuration is targeting average reservoir temperatures of over 300°C and is designed to demonstrate more than 25 megawatts of gross electric power capacity. The DOE funding will also enable Qu
From CSR to Public Health Impact: How Colgate Bright Smiles, Bright Futures® is Driving Behavior Change for the Next Billion Children and Their Families22.9.2026 16:00:00 EEST | Press release
Colgate-Palmolive, the worldwide leader in oral care, announced a strategic evolution in its flagship oral health education program, Colgate Bright Smiles, Bright Futures® (BSBF), reflecting the Company’s commitment to global public health. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922129016/en/ Launched in 1991, the program has reached over two billion children and their families across more than 100 countries, demonstrating how private-sector commitment designed to support communities, can become a powerful force for public health, driving healthier behaviors and positive outcomes at scale. From health education curriculum and school programming to mobile dental vans and free oral health screenings, BSBF helps children and their families access care, adopt healthier habits, and improve long-term oral health outcomes. “At Colgate-Palmolive, we believe oral health and healthier, brighter futures are inextricably link
Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio22.9.2026 15:30:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that data from across its Inflammation and Autoimmunity (IAI) portfolio will be presented at the European Academy of Dermatology and Venereology (EADV) 2026, held September 30 - October 3, 2026, in Vienna, Austria. "The breadth of research being presented at EADV 2026 highlights the strength of our Inflammation and Autoimmunity portfolio," said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "Data presentations in hidradenitis suppurativa, atopic dermatitis and prurigo nodularis demonstrate our commitment to advancing innovation across immune-mediated skin diseases and deepening our understanding of the patient experience." Details on key Incyte data presentations at EADV include: Oral Presentations Atopic Dermatitis Atopic Dermatitis and Life Course Disruption: Evidence From a Multidimensional International Survey (TOPiQAL) (Session: Free Communication 1: Atopic dermatitis/Eczema. Thursday, October 1, 2:50-3:0
Citi Wealth’s 2026 Global Family Office Report Reveals Clients Are Shifting Their Focus Towards Public Equities While Becoming More Deliberate and Resilient Amid Uncertainty22.9.2026 15:30:00 EEST | Press release
Citi Wealth today released its 2026 Global Family Office Report, offering an inside perspective into the thinking and behaviors of the world’s most sophisticated investors. The report was compiled by Citi Wealth’s Global Family Office Group, which works with more than 1,900 family offices worldwide. Conducted in June and July 2026, the survey sheds light on how over 350 family offices in more than 40 countries are navigating new complexities in an era defined by uncertainty. Today’s leading family offices are building long-term strategies underpinned by three key themes: capital, capability and continuity. They are investing with confidence -- becoming more institutional in how they invest, more sophisticated in how they manage risk, and more intentional in how they prepare for the future. Families also are prioritizing leadership succession and generational transition with new urgency. Key takeaways include: Strong Performance in the Face of Rising Uncertainty: Despite shifting macroe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom